Aadi Bioscience launches Fyarro in the USA
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
he financing was significantly oversubscribed with high demand from both existing and new investors.
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The facility will manufacture its Herceptin biosimilar, Tuznue
Subscribe To Our Newsletter & Stay Updated